Annals of the Rheumatic Diseases, ISSN 0003-4967, 03/2014, Volume 73, Issue 3, pp. 492 - 509
In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and...
DMARDs (biologic) | Rheumatoid Arthritis | Early Rheumatoid Arthritis | COMBINATION THERAPY | JOINT DAMAGE | INADEQUATE RESPONSE | FOLLOW-UP | RHEUMATOLOGY | ADALIMUMAB PLUS METHOTREXATE | RAPID RADIOGRAPHIC PROGRESSION | LOW-DOSE PREDNISOLONE | DMARDs (synthetic) | Treatment | TREATMENT STRATEGIES | PARALLEL-GROUP | DOUBLE-BLIND | Evidence-Based Medicine - methods | Glucocorticoids - therapeutic use | Algorithms | Arthritis, Rheumatoid - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Drug Therapy, Combination | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Biological Products - therapeutic use | Usage | Care and treatment | Antirheumatic agents | Rheumatoid arthritis | Therapeutics | Methods | Homeopathy | Materia medica and therapeutics | Task forces | Infectious diseases | Biological products | Rheumatology | Gangrene | Rheumatism | Tumor necrosis factor-TNF | TNF inhibitors | Agreements | Clinical medicine | Patients | 1506 | Recommendation
DMARDs (biologic) | Rheumatoid Arthritis | Early Rheumatoid Arthritis | COMBINATION THERAPY | JOINT DAMAGE | INADEQUATE RESPONSE | FOLLOW-UP | RHEUMATOLOGY | ADALIMUMAB PLUS METHOTREXATE | RAPID RADIOGRAPHIC PROGRESSION | LOW-DOSE PREDNISOLONE | DMARDs (synthetic) | Treatment | TREATMENT STRATEGIES | PARALLEL-GROUP | DOUBLE-BLIND | Evidence-Based Medicine - methods | Glucocorticoids - therapeutic use | Algorithms | Arthritis, Rheumatoid - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Drug Therapy, Combination | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Biological Products - therapeutic use | Usage | Care and treatment | Antirheumatic agents | Rheumatoid arthritis | Therapeutics | Methods | Homeopathy | Materia medica and therapeutics | Task forces | Infectious diseases | Biological products | Rheumatology | Gangrene | Rheumatism | Tumor necrosis factor-TNF | TNF inhibitors | Agreements | Clinical medicine | Patients | 1506 | Recommendation
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 01/2017, Volume 76, Issue 1, pp. 17 - 28
Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general...
Journal Article | FACTOR-ALPHA THERAPY | B-CELL LYMPHOMA | MODIFYING ANTIRHEUMATIC DRUGS | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | ACUTE MYOCARDIAL-INFARCTION | NECROSIS-FACTOR INHIBITORS | ANKYLOSING-SPONDYLITIS | RHEUMATOLOGY | PSORIATIC-ARTHRITIS | ACUTE CORONARY SYNDROME | DOSE GLUCOCORTICOID THERAPY | Cardiovascular Diseases - etiology | Life Style | Risk Assessment | Risk Management - methods | Cardiovascular Diseases - prevention & control | Humans | Risk Factors | Spondylitis, Ankylosing - drug therapy | Rheumatology | Spondylitis, Ankylosing - complications | Adrenal Cortex Hormones - therapeutic use | Arthritis, Rheumatoid - complications | Directive Counseling | Arthritis, Psoriatic - complications | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Arthritis, Rheumatoid - drug therapy | Arthritis, Psoriatic - drug therapy | Antirheumatic Agents - therapeutic use | Physician's Role | Epidemiologists | Complications and side effects | Care and treatment | Rheumatoid arthritis | Practice | Joint diseases | Cardiovascular diseases | Risk factors | Rheumatology and Autoimmunity | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Reumatologi och inflammation | General Practice | Allmänmedicin | Klinisk medicin
Journal Article | FACTOR-ALPHA THERAPY | B-CELL LYMPHOMA | MODIFYING ANTIRHEUMATIC DRUGS | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | ACUTE MYOCARDIAL-INFARCTION | NECROSIS-FACTOR INHIBITORS | ANKYLOSING-SPONDYLITIS | RHEUMATOLOGY | PSORIATIC-ARTHRITIS | ACUTE CORONARY SYNDROME | DOSE GLUCOCORTICOID THERAPY | Cardiovascular Diseases - etiology | Life Style | Risk Assessment | Risk Management - methods | Cardiovascular Diseases - prevention & control | Humans | Risk Factors | Spondylitis, Ankylosing - drug therapy | Rheumatology | Spondylitis, Ankylosing - complications | Adrenal Cortex Hormones - therapeutic use | Arthritis, Rheumatoid - complications | Directive Counseling | Arthritis, Psoriatic - complications | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Arthritis, Rheumatoid - drug therapy | Arthritis, Psoriatic - drug therapy | Antirheumatic Agents - therapeutic use | Physician's Role | Epidemiologists | Complications and side effects | Care and treatment | Rheumatoid arthritis | Practice | Joint diseases | Cardiovascular diseases | Risk factors | Rheumatology and Autoimmunity | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Reumatologi och inflammation | General Practice | Allmänmedicin | Klinisk medicin
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2017, Volume 76, Issue 6, pp. 960 - 977
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large...
CARDIOVASCULAR RISK-MANAGEMENT | DMARD-NAIVE PATIENTS | TREAT-TO-TARGET | STANDARDIZED OPERATING PROCEDURES | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | RHEUMATOLOGY | ADALIMUMAB PLUS METHOTREXATE | INTERLEUKIN-6 RECEPTOR INHIBITION | RAPID RADIOGRAPHIC PROGRESSION | DOSE GLUCOCORTICOID THERAPY | Glucocorticoids - therapeutic use | Humans | Patient Participation | Antibodies, Monoclonal - therapeutic use | Methotrexate - therapeutic use | Janus Kinases - antagonists & inhibitors | Time Factors | Arthritis, Rheumatoid - drug therapy | Protein Kinase Inhibitors - therapeutic use | Drug Substitution | Drug Therapy, Combination | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Life Sciences | Human health and pathology | Rhumatology and musculoskeletal system
CARDIOVASCULAR RISK-MANAGEMENT | DMARD-NAIVE PATIENTS | TREAT-TO-TARGET | STANDARDIZED OPERATING PROCEDURES | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | RHEUMATOLOGY | ADALIMUMAB PLUS METHOTREXATE | INTERLEUKIN-6 RECEPTOR INHIBITION | RAPID RADIOGRAPHIC PROGRESSION | DOSE GLUCOCORTICOID THERAPY | Glucocorticoids - therapeutic use | Humans | Patient Participation | Antibodies, Monoclonal - therapeutic use | Methotrexate - therapeutic use | Janus Kinases - antagonists & inhibitors | Time Factors | Arthritis, Rheumatoid - drug therapy | Protein Kinase Inhibitors - therapeutic use | Drug Substitution | Drug Therapy, Combination | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Life Sciences | Human health and pathology | Rhumatology and musculoskeletal system
Journal Article